ACSBG2 Inhibitors
ACSBG2 inhibitors are not inhibitors in the traditional sense of directly binding to and inhibiting the enzyme's active site. Instead, they include a diverse array of compounds that indirectly influence the cellular and biochemical pathways integral to ACSBG2's function. ACSBG2's role in lipid metabolism suggests that it may be sensitive to the availability and turnover of lipid substrates within the cell. Compounds like WY-14643 and GW7647, which are PPARα agonists, could decrease ACSBG2 activity by enhancing the catabolism of fatty acids, thereby reducing the pool of substrates that ACSBG2 would typically utilize. Such activation of lipid catabolism indirectly impedes ACSBG2's role in lipid synthesis and storage, effectively reducing its activity.
On the other hand, inhibitors of signaling pathways that potentially regulate ACSBG2's function or expression, such as Genistein, PD98059, LY294002, Wortmannin, SP600125, SB203580, and Triciribine, act by modulating the activity of kinases and phosphatases that could play a role in ACSBG2's regulation. For example, Genistein's inhibition of tyrosine kinases or PD98059's blockade of the MAPK/ERK pathway may alter the phosphorylation state of ACSBG2 or its interacting partners, thus affecting the enzyme's functionality. Similarly, inhibitors of the PI3K/AKT pathway, like LY294002 and Wortmannin, could impact ACSBG2 by altering signaling that might be critical for its role in processes such as vesicle trafficking or membrane localization, which are important for lipid metabolism.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that suppresses mTORC1 activity. mTORC1 is involved in lipid biosynthesis and autophagy. Inhibition by Rapamycin could reduce lipid modification processes that ACSBG2 may be involved in, leading to a decrease in ACSBG2 functional activity associated with lipid transport and metabolism. | ||||||
rac Perhexiline Maleate | 6724-53-4 | sc-460183 | 10 mg | $184.00 | ||
A carnitine palmitoyltransferase (CPT) inhibitor that affects lipid metabolism by preventing the transport of long-chain fatty acids into mitochondria. As ACSBG2 is implicated in fatty acid metabolism, inhibition of CPT by Perhexiline could reduce the availability of fatty acids for ACSBG2 to act upon. | ||||||
(+)-Etomoxir sodium salt | 828934-41-4 | sc-215009 sc-215009A | 5 mg 25 mg | $148.00 $496.00 | 3 | |
An irreversible inhibitor of carnitine O-palmitoyltransferase (CPT1) on the outer mitochondrial membrane, leading to decreased beta-oxidation of fatty acids. This could diminish the substrate pool for ACSBG2, indirectly decreasing its lipid-modifying activities. | ||||||
Triacsin C Solution in DMSO | 76896-80-5 | sc-200574 sc-200574A | 100 µg 1 mg | $149.00 $826.00 | 14 | |
An inhibitor of long-chain acyl-CoA synthetases (ACSLs). By inhibiting ACSLs, Triacsin C reduces the formation of acyl-CoAs, potentially decreasing substrate availability for ACSBG2, thereby reducing its activity in acyl-CoA metabolism. | ||||||
Cerulenin (synthetic) | 17397-89-6 | sc-200827 sc-200827A sc-200827B | 5 mg 10 mg 50 mg | $158.00 $306.00 $1186.00 | 9 | |
An inhibitor of the enzyme fatty acid synthase (FAS). By inhibiting FAS, Cerulenin reduces the synthesis of fatty acids, potentially diminishing the fatty acid substrates that ACSBG2 requires for its activity in lipid metabolism. | ||||||
TOFA (5-(Tetradecyloxy)-2-furoic acid) | 54857-86-2 | sc-200653 sc-200653A | 10 mg 50 mg | $95.00 $367.00 | 15 | |
An inhibitor of acetyl-CoA carboxylase (ACC), which converts acetyl-CoA to malonyl-CoA, a critical step in fatty acid biosynthesis. Inhibition by TOFA could lower malonyl-CoA levels, thereby reducing the substrate availability for lipid-related processes involving ACSBG2. | ||||||
C75 (racemic) | 191282-48-1 | sc-202511 sc-202511A sc-202511B | 1 mg 5 mg 10 mg | $71.00 $202.00 $284.00 | 9 | |
A synthetic alpha-methylene-gamma-butyrolactone that inhibits fatty acid synthase (FAS). C75 can reduce the production of new fatty acids, thereby potentially diminishing the fatty acid pool available for ACSBG2's metabolic functions. | ||||||
SBI-0206965 | 1884220-36-3 | sc-507431 | 10 mg | $122.00 | ||
An inhibitor of ULK1 kinase, which is part of the autophagy initiation complex. Since ACSBG2 is thought to participate in autophagy-related lipid metabolism, inhibition of ULK1 by SBI-0206965 could impair the autophagic process, indirectly diminishing the functional role of ACSBG2 in this pathway. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
An autophagy inhibitor that prevents the fusion of autophagosomes with lysosomes. If ACSBG2 is involved in autophagy, specifically the lipidation of autophagosome membranes, Chloroquine could disrupt this process, thereby diminishing ACSBG2's associated activity. | ||||||